Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE-3: V116 vs PCV20 in Pneumococcal Vaccine-naïve Adults
NCT05425732Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Primary completion
- May 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 11
01
Overview
A Phase 3 trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease, sponsored by Merck & Co.. Started Jul 2022; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05425732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05425732.